See more : Shalibhadra Finance Limited (SAHLIBHFI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Chembio Diagnostics, Inc. (CEMI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chembio Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Perception Capital Corp. II (PCCT) Income Statement Analysis – Financial Results
- Aenza S.A.A. (AENZ) Income Statement Analysis – Financial Results
- WalkMe Ltd. (WKME) Income Statement Analysis – Financial Results
- Victory Securities (Holdings) Company Limited (8540.HK) Income Statement Analysis – Financial Results
- Toyota Motor Corporation (TM) Income Statement Analysis – Financial Results
Chembio Diagnostics, Inc. (CEMI)
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.34M | 36.93M | 30.45M | 34.46M | 33.41M | 24.02M | 17.87M | 24.26M | 27.65M | 29.55M | 25.61M | 19.39M | 16.70M | 13.83M | 11.05M | 9.23M | 6.50M | 3.94M | 3.31M | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 38.58M | 34.50M | 23.87M | 22.39M | 21.43M | 12.92M | 9.42M | 13.77M | 16.83M | 17.25M | 14.82M | 10.00M | 8.60M | 7.97M | 7.20M | 5.37M | 4.49M | 2.61M | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.76M | 2.43M | 6.58M | 12.07M | 11.98M | 11.09M | 8.45M | 10.49M | 10.81M | 12.30M | 10.79M | 9.39M | 8.10M | 5.86M | 3.85M | 3.86M | 2.02M | 1.33M | 820.34K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 20.19% | 6.58% | 21.60% | 35.02% | 35.86% | 46.20% | 47.30% | 43.23% | 39.12% | 41.63% | 42.13% | 48.43% | 48.49% | 42.36% | 34.86% | 41.84% | 31.01% | 33.80% | 24.81% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.07M | 12.49M | 9.51M | 8.54M | 8.53M | 8.56M | 8.43M | 6.38M | 4.83M | 5.83M | 4.49M | 4.88M | 2.59M | 2.88M | 2.61M | 1.91M | 1.40M | 1.36M | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.15M | 5.73M | 4.48M | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.28K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 1.78M | 1.01M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.00 | 0.00 | 0.00 |
| SG&A | 24.28M | 24.84M | 21.04M | 16.14M | 11.10M | 9.02M | 7.60M | 7.66M | 7.50M | 5.49M | 4.85M | 3.42M | 2.94M | 2.66M | 3.32M | 4.83M | 5.20M | 3.24M | 2.49M | 3.11K | 45.05K | 6.73K | 128.83K |
| Other Expenses | -1.18M | -10.89M | -2.02M | 0.00 | 0.00 | 0.00 | 0.00 | -4.81K | -5.71K | 7.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.16M | 26.44M | 28.53M | 24.68M | 19.63M | 17.58M | 16.02M | 14.04M | 12.36M | 11.30M | 9.34M | 8.30M | 5.53M | 5.54M | 5.92M | 6.74M | 6.61M | 4.63M | 3.92M | 7.12K | 47.02K | 6.73K | 130.77K |
| Cost & Expenses | 68.74M | 60.93M | 52.40M | 47.07M | 41.05M | 30.50M | 25.44M | 27.81M | 29.20M | 28.54M | 24.16M | 18.30M | 14.13M | 13.52M | 13.12M | 12.11M | 11.10M | 7.24M | 6.41M | 7.12K | 47.02K | 6.73K | 130.77K |
| Interest Income | 0.00 | 0.00 | 0.00 | -846.83K | 49.50K | 25.43K | 25.55K | 2.41K | 5.84K | 5.78K | 7.91K | 6.30K | 4.15K | 9.03K | 34.40K | 145.29K | 29.53K | 39.80K | 8.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 382.00K | 2.91M | 2.84M | -846.83M | 0.00 | 2.95K | 0.00 | 836.00 | 0.00 | 335.00 | 9.50K | 18.62K | 14.73K | 10.60K | 8.32K | 16.88K | 386.90K | 15.68K | 190.56K | 0.00 | 635.00 | 0.00 | 14.00 |
| Depreciation & Amortization | 5.79M | 2.93M | 2.70M | 721.47K | 337.65K | 1.28M | 1.14M | 1.37M | 739.30K | 607.82K | 523.28K | 437.83K | 283.74K | 362.34K | 345.39K | 283.36K | 209.54K | 98.51K | 109.97K | 4.01K | 367.00 | 63.41K | 176.00 |
| EBITDA | -14.61M | -21.07M | -19.25M | -11.89M | -7.31M | -5.18M | -6.41M | -2.18M | -810.82K | 1.63M | 1.45M | 1.53M | 2.86M | 688.70K | -1.69M | -2.71M | -4.33M | -3.20M | -3.18M | -11.62K | -46.65K | 56.67K | -132.51K |
| EBITDA Ratio | -30.23% | -57.07% | -63.23% | -34.49% | -21.87% | -21.57% | -35.86% | -9.00% | -2.93% | 5.50% | 5.67% | 7.90% | 17.13% | 4.98% | -15.30% | -29.40% | -66.58% | -81.19% | -96.20% | 0.00% | 0.00% | 0.00% | -13,251,300.00% |
| Operating Income | -20.40M | -24.01M | -21.95M | -12.61M | -7.65M | -6.48M | -7.57M | -3.55M | -1.55M | 1.00M | 1.45M | 1.09M | 2.57M | 317.33K | -2.07M | -2.88M | -4.60M | -3.30M | -3.10M | -7.12K | -47.02K | -6.73K | -130.77K |
| Operating Income Ratio | -42.21% | -65.01% | -72.08% | -36.58% | -22.88% | -26.99% | -42.37% | -14.65% | -5.61% | 3.40% | 5.67% | 5.61% | 15.41% | 2.29% | -18.74% | -31.16% | -70.68% | -83.69% | -93.87% | 0.00% | 0.00% | 0.00% | -13,076,900.00% |
| Total Other Income/Expenses | 381.80K | -9.96M | -2.84M | -846.83K | 49.50K | 22.49K | 25.55K | -3.24K | 132.00 | 12.94K | -1.58K | -12.33K | -14.50K | -8.27K | 121.90K | 249.27K | -398.83K | 45.99K | 186.90K | 8.51K | 0.00 | -63.41K | 1.92K |
| Income Before Tax | -23.26M | -33.97M | -25.98M | -14.18M | -7.93M | -6.46M | -7.55M | -3.56M | -1.55M | 1.02M | 1.45M | 1.08M | 2.56M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -2.92M | 1.39K | 0.00 | -70.14K | -128.85K |
| Income Before Tax Ratio | -48.11% | -91.98% | -85.31% | -41.13% | -23.75% | -26.90% | -42.23% | -14.67% | -5.61% | 3.44% | 5.66% | 5.55% | 15.32% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -88.22% | 0.00% | 0.00% | 0.00% | -12,884,900.00% |
| Income Tax Expense | 34.41K | -62.05K | -456.79K | -500.29K | -67.52K | -88.31K | 5.80M | -1.16M | -412.92K | 486.95K | 509.24K | -5.13M | 45.82K | 10.60K | 8.32K | -249.27K | 398.83K | -24.12K | -4.47K | -8.51K | 635.00 | 2.67K | -1.91K |
| Net Income | -23.29M | -33.90M | -25.52M | -13.68M | -7.87M | -6.37M | -13.35M | -2.40M | -1.14M | 530.82K | 941.28K | 6.21M | 2.51M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -3.10M | 1.39K | -47.65K | -72.82K | -128.86K |
| Net Income Ratio | -48.18% | -91.81% | -83.81% | -39.68% | -23.54% | -26.53% | -74.69% | -9.88% | -4.11% | 1.80% | 3.68% | 32.02% | 15.05% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -93.74% | 0.00% | 0.00% | 0.00% | -12,886,400.00% |
| EPS | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.12 | 0.79 | 0.32 | 0.04 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| EPS Diluted | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.11 | 0.73 | 0.32 | 0.03 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| Weighted Avg Shares Out | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 8.99M | 7.99M | 7.87M | 7.76M | 7.74M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
| Weighted Avg Shares Out (Dil) | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 9.52M | 8.61M | 8.56M | 8.87M | 9.38M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
11 partai politik sepakat lawan Faida di Pilkada Jember
Wahyu Setiawan dituntut 8 tahun penjara
Man freed of murder charge after 100 court appearances - Matter should not have dragged on for so long, says Chuck
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
ISIS suspect Lisa Smith sent for trial to non-jury Special Criminal Court
Former president who brought direct elections to Taiwan dies
David Dungay: manslaughter or assault charges over death in custody are 'viable', barrister says
Appeal extends sentence review date for teenager who tried to murder woman he met on dating app
NasDem tak tahu bakal calon Bupati Gunungkidul ipar Presiden Jokowi
Appeal court adds two years to detention for minor who tried to murder woman
Source: https://incomestatements.info
Category: Stock Reports